Oral Isosorbide-5-Mononitrate Reduces the Rebleeding Rate during the Course of Injection Sclerotherapy for Esophageal Varices

References

• Westaby D, Williams R. Status for sclerotherapy for variceal bleeding in 1990. Am J Surg 1990; 160: 32–6
   PubMed Web of Science ®Google Scholar
• Terblanche J. Has sclerotherapy altered the management of patients with variceal bleeding?. Am J Surg 1990; 160: 37–42
   PubMed Web of Science ®Google Scholar
• Pagliaro L, Burroughs A K., Sorensen T IA, et al. Therapeutic controversies and randomised controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989; 2: 71–84
   Google Scholar
• Mac Dougall B RD, Westaby D, Theodossi A, et al. Increased long-term survival in variceal haemorrage using injection sclerotherapy. Lancet 1982; 1: 124–7
   PubMedGoogle Scholar
• Low D E., Kozarek R A., Ball T J., et al. Endoscopic variceal sclerotherapy as primary treatment for bleeding esophageal varices. J Clin Gastroenterol 1989; 11: 253–9
   PubMedGoogle Scholar
• Soderlund C, Ihre C. Endoscopic sclerotherapy vs conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment. Acta Chir Scand 1985; 151: 449–56
   PubMedGoogle Scholar
• EVASP. Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. N Engl J Med 1984; 311: 1594–600
   PubMed Web of Science ®Google Scholar
• Van Hootegem P H., Van Basien K, Broeckaert L, et al. Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence and survival. J Clin Gastroenterol 1988; 10: 368–72
   PubMedGoogle Scholar
• Lebrec D. Current status and future goals of the pharmacologic reduction of portal hypertension. Am J Surg 1990; 160: 19–25
   PubMed Web of Science ®Google Scholar
• Westaby D, Bihary D J., Gimson A ES, et al. Selective and non-selective beta receptor blockade in the reduction of portal pression in patients with cirrhosis and portal hypertension. Gut 1984; 25: 121–4
   PubMed Web of Science ®Google Scholar
• Gatta A, Sacerdoti D, Merkel C, et al. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotics patients with portal hypertension. Am Heart J 1984; 108: 1167–72
   PubMedGoogle Scholar
• Westaby D, Melia W, Hegarty J, et al. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology 1986; 6: 673–5
   PubMed Web of Science ®Google Scholar
• Jensen L S., Krarup N. Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. Scand J Gastroenterol 1989; 24: 339–45
   PubMed Web of Science ®Google Scholar
• Bertoni G, Fornaciari G, Beltrami M, et al. Nadolol for prevention of variceal rebleeding during the course of endoscopic injection sclerotherapy: a randomized pilot study. J Clin Gastroenterol 1990; 12: 364–5
   PubMedGoogle Scholar
• Vickers C, Rhodes J, Hillenbrand P, et al. Prospective controlled trial of propranolol and sclerotherapy for prevention of rebleeding from esophageal varices [abstract]. Gut 1987; 28: A1359
   Google Scholar
• Vinel J P., Lamouliatte H, Cales P, et al. Propranolol reduces the rebleeding rate during injection sclerotherapy: final results of a randomized study [abstract]. Gastroenterology 1989; 98: A644
   Google Scholar
• Colombo M, De Franchis R, Tommasini M, et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology 1989; 9: 433–8
   PubMed Web of Science ®Google Scholar
• Tarver D, Walt R P., Dunk A A., et al. Precipitation of hepatic encephalopathy by propranolol in man. Br Med J 1983; 287: 585
   PubMedGoogle Scholar
• Navasa M, Chesta J, Bosch J, et al. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989; 96: 1110–8
   PubMed Web of Science ®Google Scholar
• Hayes P C., Westaby D, Williams R. Effect and mechanism of action of isosorbide-5-mononitrate. Gut 1988; 29: 752–5
   PubMedGoogle Scholar
• Ikegami M, Toyonaga A, Tanikawa K. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function. Am J Gastroenterol 1992; 87: 1160–4
   PubMedGoogle Scholar
• Merkel C, Finucci G, Zuin R, et al. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. J Hepatol 1987; 4: 174–80
   PubMedGoogle Scholar
• Garcia-Pagan J C., Feu F, Navasa M, et al. Long-term hemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990; 11: 189–95
   PubMedGoogle Scholar
• Akpan W, Endel R, Neugebauer G, . Pharmacokinetics of Is-5-Mn after oral and intravenous administration in patients with hepatic failure. Mononitrates, J R. Conn, R Rittinghausen, et al. Springer-Verlag, Berlin 1985; 86–91
   Google Scholar
• Angelico M, Carli L, Di Maurizio P, et al. Isosorbide-5-mono-nitrate versus propranolol in the prevention of bleeding in portal hypertension [abstract]. Eur J Gastroenterol Hepatol 1990; 2: S4, Suppl 1
   Google Scholar
• Graham D Y., Smith J L. The course of patients after variceal hemorrhage. Gastroenterology 1980; 80: 800–9
   Google Scholar
• Pugh R NH, Murray-Lyon I M., Dawson J L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9
   PubMed Web of Science ®Google Scholar
• Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage bv esophageal endoscopv. Gastrointest Endosc 1981; 27: 213–8
   PubMed Web of Science ®Google Scholar
• Panes J, Viver J, Forne M, et al. Controlled trial of endoscopic sclerosis in bleeding peptic ulcers. Lancet 1987; 2: 1292–4
   PubMed Web of Science ®Google Scholar
• Pocock S J. Clinical trials. A clinical approach. J Wiley and Sons, London 1983
   Google Scholar
• Kaplan E L., Meyer P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457–81
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–70
   PubMedGoogle Scholar
• Poison J R., Westaby D, Gimson A ES, et al. Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices. Hepatology 1989; 10: 279–82
   PubMedGoogle Scholar
• Bonn R. Substained-release isosorbide mononitrate (50 nig): optimization of a once-daily dosage form for long-term treatment of angina pectoris. Am J Cardiol 1988; 61: 12E–4E
   Google Scholar
• Tsai Y T., Lee F Y., Lin H C., et al. Lack of effect of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. Hepatology 1989; 10: 283–7
   PubMedGoogle Scholar
• Blei A T., Garcia-Tsao G, Groszmann R J., et al. Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions. Gastroenterology 1987; 93: 576–83
   PubMedGoogle Scholar
• Kenedi P, Gathmann-Lewik U. Dose-effect relationship amongst three different substained-release forms of isosorbide-5-mononitrate in patients with coronary artery disease. Cardiology 1987; 74: 29–33, Suppl 1
   PubMedGoogle Scholar
• Heepe W, Gathmann-Lewik U. Antianginal efficacy and toler-ability of 50 mg sustained-release isosorbide-5-mononitrate in an open twelve-month observation study. Cardiology 1987; 74: 34–9, Suppl 1
   PubMedGoogle Scholar
• Freeman J G., Barton J R., Record C O. Effect of isosorbide dinitrate, verapamil and labetalol on portal pressure in cirrhosis. Br Med J 1985; 291: 561–2
   PubMedGoogle Scholar
• Garcia-Pagan J C., Feu F, Castells A, et al. Circadian variation of portal pressure in patients with cirrhosis. Relationship with variceal bleeding [abstract]. J Hepatol 1990; 11: 11, Suppl 2
   Google Scholar
• Alvarez D, Golombeck D, Viola L, et al. Circadian portal blood flow patterns in patients with cirrhosis and portal hypertension [abstract]. Gastroenterology 1992; 102(A774)
   Google Scholar